Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

NCT03875235 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

810

Enrollment

INDUSTRY

Sponsor class

Conditions

Biliary Tract Neoplasms

Interventions

DRUG: Durvalumab
DRUG: Placebo

Sponsor

AstraZeneca